The surveillance window was 21.5 months to 24.0 months for 458 patients who underwent low-intensity surveillance (88.1%) compared to 365 patients who underwent high-intensity surveillance (35.7%; P
<.001). A lower proportion of patients in the low-intensity cohort experienced a recurrence at 2 years (13.3%) versus those in the high-intensity cohort (64.1%). The median number of cystoscopies for patients who underwent low and high-intensity surveillance over at least 21.5 months was 4 and 7, respectively.2
Senior author, Florian Schroeck, MD, MS, added, "We're always looking for natural experiments so that we can get rid of some of the confounding that is often in the data…COVID-19 is an opportunity for such a natural experiment, likely starting in March in 2020, there [potentially may be] a huge drop in the number of cystoscopies, there might be none for a period of time that is likely still ongoing and will hopefully end soon. I agree that moving forward there might be an opportunity to use that data to see how [it] applies to all of the cancer care that we are currently doing and see how much of an impact it has on cancer outcomes." Schroeck is an associate professor at The Dartmouth Institute for Health Policy and Clinical Practice.
- Rezaee ME. The impact of low- vs. high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer. Presented at: American Urological Association 2020 Virtual Science Session; May 15, 2020.
- Rezaee ME, Lynch KE, Li Z, et al. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). PLoS ONE. 15(3):e0230417. doi:10.1371/journal.pone.0230417
- Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021-9. doi:10.1016/j.juro.2016.06.049
... to read the full story